GlaxoSmithKline Pharma Share Price

NSE: GLAXO

₹ 2,514.30

+₹19.30 (0.77%)

Last updated 24 Jul, 2026, 15:49 IST

GlaxoSmithKline Pharma Share Price Today

As of 25 Jul 2026, GlaxoSmithKline Pharma share price is ₹2,514.30. The stock opened at ₹2,490.20, compared to its previous close of ₹2,495.00. During today's trading session, GlaxoSmithKline Pharma share price moved in the range of ₹2,455.00 to ₹2,525.80, with an average price of ₹2,490.40 for the day. Looking at its last 52-week, the stock has touched a low of ₹2,088.10 and a high of ₹3,200.00. On the performance front, GlaxoSmithKline Pharma share price has increased by 8.68% over the last six months and is down 20.49% on a year-on-year basis.

₹2,455.00

0.77% up today

₹2,525.80

1D LOW

1D HIGH

Latest Earning

Op Profit TrendUp by 11.60% YoY

Latest Earning

Net Profit TrendUp by 11.69% YoY

Latest Earning

Revenue TrendUp by 1.85% YoY

Stock Performance

OutperformingBeat Nifty by 8.47 % in last 1 month

Shareholding Pattern

DIIDII decreased stake by 0.67%

Shareholding Pattern

FIIFII increased stake by 3.55%

GlaxoSmithKline Pharma Returns Calculator

If you would've invested

₹

₹1,000₹1Cr

Historical Returns

1 Year

₹3,99,831-₹1,00,169 (-20.03%)

3 Year

₹9,00,473+₹4,00,473 (+80.09%)

5 Year

₹7,81,931+₹2,81,931 (+56.39%)

₹2,011.50₹3,017.10

Circuit Low

Circuit High

₹2,088.10₹3,200.00

52-Week Low

52-Week High

Circuit

₹2,011.50

₹3,017.10

52-week

₹2,088.10

₹3,200.00

Mkt Cap Cr

42,253.20

P/E

37.34

P/B

17.06

ROE

49.11%

D/E

0.01

ROCE

59.05%

Div. Yield

2.50%

EPS(TTM)

59.59

Turnover

1.51

EV/EBITDA

25.30

Net Margin

26.70%

Op. Margin

38.14%

ROA

40.46%

Quick Ratio

1.77

Curr. Ratio

1.28

Mkt Cap Cr

42,253.20

P/E

37.34

P/B

17.06

ROE

49.11%

D/E

0.01

ROCE

59.05%

Div. Yield

2.50%

EPS(TTM)

59.59

Turnover

1.51

EV/EBITDA

25.30

Net Margin

26.70%

Op. Margin

38.14%

ROA

40.46%

Quick Ratio

1.77

Curr. Ratio

1.28

Based on fundamentals, this stock's

Performance

Excellent

Glaxosmi. Pharma outperforming all market indices

Valuation

Overvalued

Glaxosmi. Pharma appears overvalued compared to its peers

Earnings

Neutral

Glaxosmi. Pharma earnings growth is positive

Peer Comparison

Peer comparison — key ratios
Name	Mkt Cap Cr	P/E	P/B	ROE	D/E	ROCE	Book Value	Div. Yield	Turnover	EPS(TTM)
Sun Pharmaceutical Industries	4,65,711.00	36.73	5.05	14.85%	0.55	18.72%	18.85	0.91%	0.56	10.90
Divis Laboratories	1,93,860.00	61.36	9.40	16.19%	0.00	21.00%	9.43	0.50%	0.58	98.19
Torrent Pharmaceuticals	1,92,687.00	66.03	17.03	26.76%	1.05	18.30%	16.90	0.90%	0.49	64.75
Cipla	1,12,593.00	33.55	3.27	11.27%	0.00	14.95%	423.36	0.93%	0.44	43.52
Zydus Lifesciences	1,11,082.00	17.39	3.23	19.69%	0.35	20.30%	3.70	0.11%	0.39	35.38
Lupin	1,09,553.00	19.83	4.71	27.01%	0.03	27.44%	3.51	0.78%	0.61	129.18
Mankind Pharma	1,03,472.00	1.05	0.12	12.65%	0.42	12.97%	5.05	0.05%	0.54	49.37
Dr. Reddy's Laboratories	96,204.70	30.22	2.53	11.07%	0.18	12.54%	377.96	0.69%	0.41	38.68
Aurobindo Pharma	88,508.40	25.27	2.34	9.25%	0.19	11.76%	391.14	0.26%	0.48	41.58
Laurus Labs	84,727.30	60.26	10.10	18.21%	0.40	16.70%	97.21	0.12%	0.64	13.72

GlaxoSmithKline Pharma Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Revenue	₹3,821.67	₹3,749.21	₹3,453.71	₹3,251.72
Other Income	₹145.36	₹145.93	₹122.59	₹100.66
Total Revenue	₹3,967.03	₹3,895.14	₹3,576.30	₹3,352.38
Total Expenses	₹2,581.65	₹2,639.95	₹2,616.50	₹2,515.02
Profit Before Tax	₹1,406.01	₹1,259.88	₹816.19	₹836.40
Tax	₹370.03	₹332.30	₹226.23	₹228.76
Profit After Tax	₹1,035.98	₹927.58	₹589.96	₹607.64
EPS - Basic	₹61.15	₹54.76	₹34.83	₹36.05
EPS - Diluted	₹61.15	₹54.76	₹34.83	₹36.05

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Profit before tax	₹1,385.39	₹1,255.19	₹959.80	₹841.49
Income before WC changes	₹1,320.14	₹1,186.78	₹914.67	₹801.49
Change in Assets	₹55.14	₹29.53	-₹107.15	₹51.14
Change in Liabilities	-₹153.31	₹155.30	₹168.17	-₹96.89
Change in WC	-₹98.17	₹184.83	₹61.02	-₹45.75
Cash flow from Operations	₹903.30	₹1,289.90	₹582.02	₹484.23
Cash flow from Investing	₹396.98	-₹45.80	₹8.71	₹807.85
Cash flow from Financing	-₹737.08	-₹769.42	-₹561.50	-₹1,543.32
Total Cash Flow	₹563.20	₹474.68	₹29.23	-₹251.25
Cash (Start of the year)	₹538.85	₹64.17	₹34.94	₹286.19
Cash (End of the year)	₹1,102.05	₹538.85	₹64.17	₹34.94

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Non-Current Assets	₹717.67	₹698.18	₹758.20	₹832.32
Current Assets	₹3,606.20	₹3,409.88	₹2,798.42	₹2,494.26
Total Assets	₹4,323.87	₹4,108.07	₹3,556.62	₹3,326.58
Current Liabilities	₹1,779.10	₹1,905.15	₹1,524.95	₹1,326.37
Net Current Asset	₹1,827.09	₹1,504.73	₹1,273.47	₹1,167.89
Non-Current Liabilities	₹277.35	₹251.60	₹254.03	₹258.94
Equity Capital	₹2,267.42	₹1,951.31	₹1,777.64	₹1,741.27
Total Equity & Liabilities	₹4,323.87	₹4,108.07	₹3,556.62	₹3,326.58

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Revenue	₹3,790.20	₹3,723.49	₹3,407.25	₹3,216.34
Other Income	₹142.56	₹142.56	₹123.48	₹101.51
Total Revenue	₹3,932.76	₹3,866.05	₹3,530.73	₹3,317.86
Total Expenses	₹2,559.17	₹2,622.31	₹2,578.08	₹2,484.50
Profit Before Tax	₹1,376.23	₹1,248.44	₹809.04	₹832.39
Tax	₹364.40	₹329.39	₹224.35	₹227.69
Profit After Tax	₹1,011.82	₹919.05	₹584.69	₹604.71
EPS - Basic	₹59.59	₹54.01	₹34.51	₹35.88
EPS - Diluted	₹59.73	₹54.24	₹34.51	₹35.88

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Profit before tax	₹1,373.59	₹1,243.74	₹952.65	₹837.49
Income before WC changes	₹1,308.77	₹1,174.77	₹906.51	₹796.63
Change in Assets	₹62.42	₹22.37	-₹100.82	₹42.28
Change in Liabilities	-₹169.67	₹163.81	₹165.37	-₹81.30
Change in WC	-₹107.25	₹186.18	₹64.55	-₹39.02
Cash flow from Operations	₹881.42	₹1,280.03	₹578.94	₹487.94
Cash flow from Investing	₹385.25	-₹36.53	₹14.97	₹805.19
Cash flow from Financing	-₹737.07	-₹769.42	-₹561.50	-₹1,544.18
Total Cash Flow	₹529.60	₹474.07	₹32.41	-₹251.05
Cash (Start of the year)	₹536.22	₹62.15	₹29.74	₹280.79
Cash (End of the year)	₹1,065.82	₹536.22	₹62.15	₹29.74

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Non-Current Assets	₹731.79	₹717.38	₹781.96	₹860.98
Current Assets	₹3,543.12	₹3,383.55	₹2,765.84	₹2,466.72
Total Assets	₹4,274.91	₹4,100.93	₹3,547.80	₹3,327.70
Current Liabilities	₹1,757.11	₹1,900.81	₹1,510.94	₹1,317.03
Net Current Asset	₹1,786.01	₹1,482.73	₹1,254.90	₹1,149.69
Non-Current Liabilities	₹276.63	₹250.89	₹252.76	₹257.67
Equity Capital	₹2,241.17	₹1,949.23	₹1,784.09	₹1,753.00
Total Equity & Liabilities	₹4,274.91	₹4,100.93	₹3,547.80	₹3,327.70

* All values are in INR Crore

Qty

Bid

2514.3

Ask

Qty

Bid Total: 38

Ask Total: 0

Buy orders: 100%

Sell orders: 0%

30 levels of bid & ask depth

Supply & Demand Zones

Bearish

Neutral

Bullish

Slightly Bullish

by SEBI experts available for this stock

Earn more using advisory

by SEBI experts

Expert Pick

EXPPICK

Stop-loss

Entry price

Target

Indicator

Value

Verdict

RSI (14)

59.56

Neutral

ATR (14)

57.53

Neutral

STOCH(9,6)

54.18

Neutral

STOCH RSI (14)

1.08

Bullish

ADX(9)

42.42

Bearish

UO(9)

59.21

Neutral

ROC(12)

3.68

Bullish

WillR(14)

-37.5

Neutral

Period

Simple value

Exponential vaue

2498.46

2502.5

10D

2480.44

2481.9

20D

2444.99

2441.11

50D

2338.84

2389.48

100D

2382.74

2391.87

About GlaxoSmithKline Pharma

ISIN

INE159A01016

Sector Market Cap

₹ 42,253.2 Cr

GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company has three product areas: vaccines, specialty and general medicine. Its general medicines business has a portfolio of medicines in anti-infectives, pain, vitamins medicine, nutritional, hormones, dermatologicals, respiratory and vaccines for adults and children. The Company's general medicine brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, Tenovate, T-bact and Physiogel. The Company's vaccine brands include Shingrix Herpes Zoster Vaccine, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicine brands include Nucala, Seretide, and Trelegy Ellipta. Trelegy Ellipta, single inhaler triple therapy (SITT) for chronic obstructive pulmonary disease (COPD) patients. The Subsidiary of the Company is Biddle Sawyer Limited.

GlaxoSmithKline Pharma Financial Highlights

Revenue: GlaxoSmithKline Pharma reported revenue of ₹3,967.03 crore in FY26 vs ₹3,895.14 crore in FY25. It showed an increase of 1.85% on a yearly basis.
Operating Profit: GlaxoSmithKline Pharma reported an operating profit of ₹1,406.01 crore in FY26 vs ₹1,259.88 crore in FY25. It showed an increase of 11.60% on a year-on-year basis.
Net Profit: GlaxoSmithKline Pharma reported a net profit of ₹1,035.98 crore in FY26 vs ₹927.58 crore in FY25. It showed an increase of 11.69% on a yearly basis.

GlaxoSmithKline Pharma Quarterly Result Highlights

GlaxoSmithKline Pharma reported revenue of ₹1,031.25 crore in Mar 2026, compared with ₹1,073.38 crore in Dec 2025, representing a decrease of 3.92% on a quarter-on-quarter (QoQ) basis.
GlaxoSmithKline Pharma reported an operating profit of ₹373.10 crore in Mar 2026, compared with ₹399.93 crore in Dec 2025, representing a decrease of 6.71% on a quarter-on-quarter (QoQ) basis.
GlaxoSmithKline Pharma reported a profit of ₹277.86 crore in Mar 2026, compared with ₹295.62 crore in Dec 2025, reflecting a decrease of 6.01% on a QoQ basis.
The earnings per share (EPS) of GlaxoSmithKline Pharma stood at ₹61.15 during Mar 2026.